Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

This study has been completed.
Sponsor:
Collaborator:
Genentech
Information provided by (Responsible Party):
Vitreo-Retinal Associates, PC
ClinicalTrials.gov Identifier:
NCT01472510
First received: November 3, 2011
Last updated: March 13, 2014
Last verified: March 2014
  Purpose

This study is designed to confirm that the investigational drug Ranibizumab given by injection into the eye is safe and effective to use in people with diabetic macular edema (DME).


Condition Intervention Phase
Diabetic Macular Edema
Drug: Ranibizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

Resource links provided by NLM:


Further study details as provided by Vitreo-Retinal Associates, PC:

Primary Outcome Measures:
  • Change in Visual Acuity Scores at Month 12 Compared to Baseline [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Resolution of residual edema compared to baseline as determined by mean foveal thickness on Cirrus OCT 300 microns at Month 6 and Month 12. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: December 2011
Study Completion Date: January 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1:The PRN Group
You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
Drug: Ranibizumab
A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Other Name: lucentis
Active Comparator: arm 2:The Monthly Group:
You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
Drug: Ranibizumab
A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Other Name: lucentis

Detailed Description:

Ranibizumab works by blocking Vascular Endothelial Growth Factor (VEGF), a substance which is found in eyes with diabetic eye disease and which causes leakage from blood vessels. Several studies have suggested that eyes with DME may have very high levels of VEGF; therefore, Ranibizumab may be helpful in blocking VEGF and decreasing DME.

Ranibizumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD) and Retinal Vein Occlusion at the dose amount of 0.5 mg. Ranibizumab has not been approved for use in subjects with DME.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will be eligible if the following criteria are met:

    1. Age > 18 years
    2. Diagnosis of diabetes mellitus (type 1 or 2)
    3. Residual edema as determined by mean foveal thickness on Cirrus OCT > 300 microns and leakage seen on FA at baseline
    4. Clinical evidence of retinal thickening due to macular edema involving the center of the macula, associated with diabetic retinopathy.
    5. Previous history of at least 4 or more consecutive anti-VEGF intravitreal injections of Pegaptanib sodium or Bevacizumab (consecutive injections administered no more than 6 weeks apart in the last year) for the treatment of diabetic macular edema.
    6. Previous history of focal laser and/or intravitreal steroid injection for the treatment of diabetic macular edema.
    7. BCVA of 20/32-20/400 (ETDRS)
    8. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography

Exclusion Criteria:

  1. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception. . The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
  2. Participation in another ocular investigation or trial simultaneously.
  3. Systemic use of anti-VEGF within 3 months prior to day 0.
  4. Previous intravitreal ranibizumab within 3 months prior to day 0
  5. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110)
  6. Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse).
  7. Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be contributing to the macular edema.
  8. An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis, ischemic maculopathy or geographic atrophy).
  9. Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gass).
  10. Evidence of active neovascularization of the iris or retina.
  11. Evidence of central atrophy or fibrosis in the study eye.
  12. Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
  13. History of vitreous surgery in the study eye.
  14. History of cataract surgery within 6 months of enrollment.
  15. History of YAG capsulotomy within 2 months of enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01472510

Locations
United States, Massachusetts
Vitreo-Retinal Associates, PC
Worcester, Massachusetts, United States, 01605
Sponsors and Collaborators
Vitreo-Retinal Associates, PC
Genentech
Investigators
Principal Investigator: Frank J McCabe, M.D. Vitreo-Retinal Associates, PC
Study Director: Marie V Lampson Vitreo-Retinal Associates, PC
  More Information

No publications provided

Responsible Party: Vitreo-Retinal Associates, PC
ClinicalTrials.gov Identifier: NCT01472510     History of Changes
Other Study ID Numbers: ML27906
Study First Received: November 3, 2011
Last Updated: March 13, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Vitreo-Retinal Associates, PC:
Diabetic
Macular
Edema
Ranibizumab
anti-VEGF

Additional relevant MeSH terms:
Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014